Skip to content
Home page - Centenary Institute Centenary Institute

Primary menu

  • Research
        • Research

          The latest medical research into our most complex health challenges across cancer, cardiovascular disease and inflammation

          Learn more

        • Cancer
        • Inflammation
        • Cardiovascular
        • Programs
        • Laboratories
        • Diseases
        • Expertises
        • Services and instrumentation
  • Support us
        • Support us

          By supporting the Centenary Institute you can help improve human health through excellence in medical research

          Learn more

        • Workplace giving
        • Host or join a fundraiser
        • Gift in your will
        • Donate in Memory
  • Impact
        • Impact

          Our research develops new diagnostics, treatments and cures for some of the most deadly and debilitating diseases affecting society today

          Learn more

        • Breakthroughs
        • Community and research
  • Careers & studies
        • Careers & Studies

          Take the next step in your career with Centenary, Australia’s foremost clinically integrated medical research institute

          Learn more

        • Career opportunities
        • Life at Centenary
        • Post-Doctorate Research
        • PhD
        • Masters
        • Honours
  • News & events
        • News & Events

          Explore the latest research breakthroughs and ways you can take part in our series of digital and in-person events

        • News
        • Events
        • Media Hub
  • About us
        • About us

          We are world-leading independent medical research institute that drives collaboration to accelerate and translate solutions to our most complex health challenges

          Learn more

        • Governance
        • Corporate information
        • Annual reports
        • Our researchers
        • Contact
  • Donate
    Centenary Institute > News > Gene discovery linked to alcohol-induced liver disease

Gene discovery linked to alcohol-induced liver disease

Date time 27 August, 2020
News Type News type Media release
The findings of an international study led by the Centenary Institute suggests that the possibility of high-risk drinkers developing alcohol-induced cirrhosis is in part related to genetic factors.

The findings of an international study led by the Centenary Institute suggests that the possibility of high-risk drinkers developing alcohol-induced cirrhosis is in part related to genetic factors.

“Only a small proportion of high-risk drinkers, about 15 percent, actually develop cirrhosis but those who do are at high risk of death and require substantial health-care support,” said senior author of the published study Clinical Associate Professor Devanshi Seth, Head of the Centenary Institute Alcoholic Liver Disease Research Program and also affiliated with Drug Health Services, Royal Prince Alfred Hospital, Sydney Local Health District.

“We wanted to see if certain high-risk drinkers had a genetic predisposition for alcohol-induced cirrhosis. High-risk drinking is chronic alcohol use above recommended guidelines,” said Clinical Associate Professor Seth.

Reported in the science journal ‘Hepatology’ the study was undertaken by a multi-national GenomALC Consortium involving the Southern California Institute for Research and Education (SCIRE) and other research collaborators.

Identified by the study researchers is a new gene associated with alcohol-induced cirrhosis. The novel FAF2 gene is associated with a reduced cirrhosis risk for heavy drinkers. Also confirmed by the study were four additional genes, three previously found to be associated with an increased risk and one with reduced risk of cirrhosis in heavy drinkers.

“Interestingly, a commonality of these genes, including the novel FAF2, is that they appear to affect the lipid (fat) metabolism pathway,” said Clinical Associate Professor Seth.

“The findings are important as due to heavy drinking, it is the build-up of lipid droplets in the liver, that can cause inflammation, and which may then lead to serious liver complications such as cirrhosis in some drinkers,” she said.

The researchers believe that the identified genes are influencing the body’s ability to regulate lipid droplets in the liver and are therefore influencing cirrhosis risk levels.

“This new understanding opens the door to the future development of exciting new drug treatments that can potentially target these specific genes and lipid processes, and reduce the chances of at-risk individuals contracting this devastating disease,” said Dr Timothy Morgan, co-senior author of the study and researcher at the SCIRE.

Clinical Associate Professor Seth says, “Abstaining or reducing alcohol use remains the most effective treatment, however fully understanding the genetic mechanics of alcohol-induced cirrhosis is also key to improving patient diagnosis and treatment decisions.”

“Identifying these genes at an individual level, in combination with assessing lifestyle options, means that we will now be able to predict an individual’s risk profile and then better personalise an appropriate treatment response,” she said.

The research was funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) a part of the National Institutes of Health (NIH), USA.

Read the full media release here.

Publication: Genome-wide association study and meta-analysis on alcohol-related liver cirrhosis identifies novel genetic risk factors.

Themes

  • Inflammation

    Inflammation

Media enquires

For all media and interview enquiries, please contact Tony Crawshaw, Media and Communications Manager

Phone number Phone Number 0402 770 403

Email Email t.crawshaw@centenary.org.au

Media Release

Download

Recent Stories

  • New drug target identified for inflammatory lung disease

    Researchers at the Centenary Institute and the University of Technology Sydney have identified a new drug target for the treatment and prevention of chronic obstructive pulmonary disease (COPD), an inflammatory lung disease that causes airway blockage and that makes it difficult to breathe.
    News Type: Media release
    Date 04 Jul 2022
  • Inflammation presentation awarded

    Dr Joyce Chiu from the ACRF Centenary Cancer Research Centre has won an Oral Communication Award for her talk given at the 15th World Congress on Inflammation, held in Rome, June 2022.
    News Type: Research News
    Date 01 Jul 2022
  • Meet Dr Annalicia Vaughan

    A medical researcher at the Centenary UTS Centre for Inflammation, Dr Annalicia Vaughan specialises in the gut-lung axis and its role in lung and respiratory diseases.
    News Type: Profiles
    Date 28 Jun 2022
    Dr Vaughan
  • The Centenary Institute is excited to join the Sydney Biomedical Accelerator (SBA) as primary medical research partner

    The Centenary Institute welcomes the NSW Government’s commitment to fund a new biomedical complex in Camperdown. The Chair of the Centenary Institute Board, Joseph Carrozzi AM, and its Executive Director, Professor Mathew Vadas AO, are thrilled that a biomedical complex, the Sydney Biomedical Accelerator (SBA), will now be a reality.
    News Type: Media release
    Date 17 Jun 2022

Subscribe to receive news on
research updates and free events

Newsletter

The Centenary Institute is a world-leading independent Medical Research Institute.

We acknowledge the Gadigal of the Eora Nation, the traditional custodians of the Country on which the Centenary Institute stands.

About

  • About
  • Governance
  • Corporate information

Research

  • Programs
  • Laboratories
  • Our researchers
  • News
  • Media hub

Careers & studies

  • Career opportunities
  • Life at Centenary

Links

  • Contact
  • Privacy statement

Contact us

Building 93, Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050 Australia
Telephone +61 2 9565 6100
Fax +61 2 9565 6101

Centenary Institute ABN 22 654 201 090 (DGR 1) • Centenary Institute Medical Research Foundation ABN 85 778 244 012 (DGR 2)
© 2017 Centenary Institute of Cancer Medicine and Cell Biology.

  • Linkedin
  • Facebook
  • Twitter
  • Youtube
  • Instagram